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Available online at www.sciencedirect.comSaphenous vein grafts used in coronary artery bypass graft
surgery suffer from lower patency rates compared to left
internal mammary artery. A number of clinical trials and
observational studies have demonstrated a significant benefit
of statin treatment on vein graft patency. Aside from their well-
known lipid-lowering capacities, statins exert pleiotropic
effects by direct inhibition of the mevalonate pathway in the
wall of these grafts. This leads to reduced geranylgeranylation
of small GTPases such as Rho and Rac. Through this LDL-
independent mechanism, statins improve endothelial function
and reduce vascular inflammation and oxidative stress,
inhibiting also smooth muscle cell proliferation and migration.
Although the existing evidence supports a beneficial effect of
statins on vein grafts biology, more clinical trials focused on the
effect of aggressive statin treatment on vein graft patency are
required, in order to safely translate this strategy into clinical
practice.
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Coronary artery bypass grafting (CABG) surgery is still
undoubtedly a first line option for the treatment of
advanced coronary artery disease (CAD). Although internal
mammary artery (IMA) is the conduit of choice in most of
the cases, the need for more than one grafts makes au-
tologous saphenous vein grafts (SVGs) the most common
type of graft in the vast majority of CABG operations.
Although clinical outcome post CABG in diabetics and
patients with multivessel CAD is better compared to
percutaneous coronary intervention (PCI) [1], CABG is
not spared of complications, both peri-operative and post-
operative, which could threaten the patient’s recuperation
[2]. SVG use is especially plagued by concerns over long-
term patency, with up to 20% of grafts failing in only the
first year after surgery [3].
Open access under CC BY-NC-ND license. Current Opinion in Pharmacology 2012, 12:172–180 Diverse pharmacological treatment has been extensively
used as an adjuvant to CABG, either to minimize com-
plications or improve long-term outcome. In this sense
statins, with their extensively discussed lipid-lowering
and pleiotropic effects, have been prime candidate drugs
for improvement of post-operative outcome in CABG
patients. In this review we summarize the clinical data
regarding statin use and SVG patency and discuss the
specific effects of statins on SVG biology.
Vein graft failure and determining factors
The most common mechanisms mediating SVG failure are
acute thrombosis and intimal hyperplasia in the first year
after surgery, and atherosclerosis in later stages [4]. Apart
from the well-known risk factors, such as smoking and
hyperlipidemia, the fate of the SVG can be influenced by
other determinants such as vessel diameter, surgical tech-
nique and others [4]. For example, off-pump CABG has
suffered from lower long-term SVG patency rates than on-
pump [2]. Using longitudinal analysis in a population of
50,278 patients, patency rates for the first 1, 5 and 10 years
after surgery were 78%, 65%, and 57% for SVGs and 93%,
88%, and 90% for IMA grafts, respectively [3], stressing the
fact that SVGs are a rather weak graft, that could potentially
be improved by adjuvant pharmaceutical interventions.
Statins and clinical outcome post CABG
During the last decade, statins have been established as
mainstay in secondary prevention following cardiovascu-
lar events. Initiation of statin treatment improves clinical
outcome after an acute coronary syndrome (ACS) [5] and
long-term statin administration significantly reduces all-
cause mortality in patients with CAD [6].
The potential role of intensive statin therapy during the
CABG periprocedural period has been the focus of exten-
sive research. Treatment with fluvastatin 80 mg/day for
up to 37 days before vascular surgery reduced major
adverse cardiovascular events during the post-operative
period, with few side effects [7]. In addition, preoperative
treatment with atorvastatin 20 mg/day for 3–7 days prior-
CABG consistently reduced the incidence of paroxysmal
atrial fibrillation [8,9]. However, a meta-analysis of 21
randomized statin trials using post-procedural myocardial
infarction as primary endpoint revealed a strong protec-
tive effect of statins post PCI and non-cardiac procedures
but only a trend for CABG, a finding that is possibly due
to the smaller number of CABG studies available [10].
In the context of SVG disease, the landmark POST-CABG
multi-centre randomized trial showed that intensive LDL-
lowering treatment with lovastatin  cholestyramine afterwww.sciencedirect.com
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obstructive atherosclerotic changes in SVGs compared to
more conservative treatment (target levels below 140 mg/
dl) [11]. In the same study population, a similar beneficial
effect of intensive lipid-lowering treatment was also
observed for atherosclerosis progression in the native cor-
onary arteries [12]. A more recent randomized trial revealed
significant benefits of aggressive statin therapy (atorvasta-
tin 80 mg/day vs. 10 mg/day) on the risk of post-operative
complications including the need for coronary revascular-
isation after CABG, with median LDL levels reaching
79 mg/dl in the intensive treatment group [13]. Intensive
lipid control was also shown to inhibit yellow plaque and
thrombus formation in SVGs, as demonstrated by intra-
vascular ultrasound [14]. The latest ACC/AHA guidelines
for CABG affirm the pivotal role of statins in LDL-low-
ering therapy for SVG disease prevention and recommend
optimal treatment with LDL target levels <100 mg/dl and
even <70 mg/dl in high-risk patients [15].
Although statins are traditionally thought to exert their
beneficial effects on SVG patency through lipid lowering,
there are clinical data suggesting additional mechanisms
involved. Analysis of the POST-CABG trial population
revealed a significant protective effect of intensive vs.
moderate statin treatment on incidence of SVG resteno-
sis, independently of LDL lowering [16]. This study was
the first proof in a clinical setting for the existence of a
dose-dependent effect of statins on SVG patency that is
independent of LDL-lowering. Table 1 summarizes
important clinical trials involving statin administration
in CABG patients.
The mevalonate pathway: a way towards the
vascular pleiotropic effects of statins
Statins exert their effects through inhibition of 3-
hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)
reductase by blocking substrate binding to the active site
of the enzyme [17]. The NADPH-mediated reduction of
HMG-CoA is the rate-limiting step in the mevalonate
pathway, which is responsible for endogenous cholesterol
biosynthesis in humans. The mevalonate pathway uses
acetyl-CoA as basis for synthesis of dimethylallyl pyro-
phosphate (DMAPP) and isopentenyl pyrophosphate
(IPP), themselves precursors to isoprenoids and consecu-
tively squalene and cholesterol synthesis. Thus, by inhi-
biting the mevalonate pathway, statins lead to reduction
in endogenous cholesterol production and LDL levels,
because cholesterol is a major component of the LDL
molecule [18]. Reduced LDL levels result in lower
oxidized LDL (oxLDL) and therefore attenuation of
the atherosclerotic process (Figure 1).
In addition, the isoprenoids farnesylpyrophosphate (FPP)
and geranyl-geranyl-pyrophosphate (GGPP), downstream
intermediates of the mevalonate pathway, are important
mediators of protein prenylation, which is a post-transla-www.sciencedirect.com tional modification involving addition of isoprene units.
Major targets of protein prenylation are the family of small
GTPases (Rho, Rac, Ras, among others). Geranyl-gerany-
lation of Rho allows lipid anchoring to the membrane and
activation of Rho kinases (ROCKs), whereas Rac1 is
implicated, among others, in reactive oxygen species
(ROS) generation [19]. Because the mevalonate pathway
is active in vascular cells (endothelial, vascular smooth
muscle cells and others), it is inhibited by statins in these
cells as well. This explains a significant portion of what is
known as the ‘pleiotropic effects’ of statins [18].
Statins and vein graft failure: mechanistic
insights
Statins and endothelial function of SV grafts
SVG endothelium is especially prone to disruption and
dysfunction due to the harvesting process and exposure to
arterial blood flow. Endothelial dysfunction, character-
ized by reduced nitric oxide (NO) bioavailability appears
in both arterial and venous endothelium in a similar way
[20]. Although the role of endothelial dysfunction in
atherogenesis is well documented, the vast majority of
the literature is focused on the arterial wall, and data on
the role of NO bioavailability in veins are limited. How-
ever, it is widely accepted that endothelial function is a
key feature in SVG homeostasis and that endothelial NO
bioavailability in SV grafts is a rational therapeutic target
in CABG surgery. Indeed, NO produced by SVGs may
play a critical role in short-term and long-term grafts
patency, as it has vasorelaxant, antithrombotic and anti-
inflammatory properties [21]. Moreover, long-term main-
tenance of sufficient NO bioavailability may also exert
antiatherogenic effects in these grafts, improving their
long-term patency, although this is hard to be tested in
clinical studies.
Aggressive statin treatment has been associated with
improved endothelial function of SVGs in a clinical
observational study [22], while in a randomized trial, 4-
weeks treatment with simvastatin significantly improved
endothelial function evaluated by flow-mediated dilata-
tion compared to ezetimibe, an effect that was indepen-
dent of LDL-lowering [23]. LDL cholesterol is a major
determinant of endothelial dysfunction in SVGs [24] and
even short-term statin treatment prior-CABG leads to a
rapid improvement of endothelial function in both
arteries and veins [25]. However, it had been demon-
strated that statins exert a direct effect on endothelial
function by directly inhibiting HMG-CoA reductase in
the vascular wall, independently of any effects on LDL
levels, identifying the mevalonate pathway as a rational,
direct therapeutic target for the improvement of SVGs
biology [18,25].
Incubation of isolated endothelial cells from SVGs with
cerivastatin significantly increased endothelial nitric
oxide synthase (eNOS) expression and subsequentlyCurrent Opinion in Pharmacology 2012, 12:172–180
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stabilization of eNOS mRNA through statin-mediated
inhibition of Rho geranylgeranylation [27]. Incubation of
human umbilical vein endothelial cells (HUVECs) with
simvastatin or fluvastatin, activated the phosphatidylino-
sitol 3-kinase (PI3K)/protein kinase Akt pathway, leading
to enhanced phosphorylation of eNOS and increased
activity [28,29]. Similarly, incubation of HUVECs with
various statins inhibited H2O2-induced endothelial
senescence by increasing eNOS and sirtuin 1 expression
[30]. Moreover, treatment of apolipoprotein E knockout
mice with rosuvastatin significantly reduced caveolin-1, a
molecule that binds to eNOS inhibiting its enzymatic
activity [31]. Therefore, statin treatment improves both
eNOS gene expression and activity, through distinct
mechanisms, contributing to increased bioavailability of
NO and improved endothelial function.
The ability of eNOS to produce NO is dependent on the
binding of its essential co-factor tetrahydrobiopterin
(BH4), a process known as ‘coupling’ of the enzyme
[32]. GTP cyclohydrolase (GTPCH) is the rate-limiting
enzyme in BH4 biosynthesis. Incubation of HUVECs
with fluvastatin significantly upregulated GTPCH gene
expression and improved NO release [29]. Similarly, in
streptozotocin-induced diabetic rats, oral atorvastatin
increased GTPCH levels and ameliorated eNOS
coupling [33].
We have recently shown that 3-day preoperative, high-
dose atorvastatin treatment improves endothelial func-
tion and vascular redox state, by improving eNOS
coupling in both SVG [25] and IMA grafts [34]; this
is mediated by increased BH4 bioavailability as a result of
upregulation of GCH1 gene, encoding GTPCH [34].
This effect is due to direct inhibition of HMG-CoA
reductase within the vascular wall, independently of
LDL lowering.
Furthermore, the role of statins in promoting endothelial
progenitor cells (EPCs) re-endothelialisation of SVGs
post CABG has been extensively studied. In patients
with stable angina, 4-week treatment with atorvastatin
40 mg/day led to significantly elevated levels and func-
tional activity of marrow-derived circulating EPCs [35],
an effect mediated by the PI3K/Akt pathway [35]. Treat-
ment of EPCs with atorvastatin attenuated homocys-
teine-induced dysfunction through an AMP-activated
protein kinase (AMPK) dependent mechanism [36],
while high dose of statin treatment lead to further im-(Figure 1 Continued) (a) The mevalonate pathway and pleiotropic effects o
statins on vascular smooth muscle cells. HMG-CoA: 3-hydroxy-3-methyl-glut
pyrophosphate; GPP: geranyl pyrophosphate; FPP: farnesyl pyrophosphate; 
NADPH: nicotinamide adenine dinucleotide phosphate; BH4: tetrahydrobiop
inducible nitric oxide synthase; NO: nitric oxide; ROCK: rho kinase; PI3K: p
cyclohydrolase; NF-kB: nuclear factor kappa-b; IkB: inhibitor of kappaB; LD
species; VSMC: vascular smooth muscle cell; MMP: matrix metalloproteina
www.sciencedirect.com provement of EPCs function compared to low dose [37].
Figure 1 illustrates the effects of statins on endothelial
cell physiology.
Statins and vasospasm/acute thrombosis of
SV grafts
Vasoconstrictor agents such as endothelin-1 (ET1) and
angiotensin counteract the vasodilatory effects of NO
and have potential implications in VSMC migration/
hyperplasia and neointima formation [38]. Statins were
found to inhibit preproendothelin-1 gene expression
through a Rho-mediated mechanism [39]. In addition,
simvastatin inhibited ET1-mediated contraction in rat
aortic rings, an effect that was reversed by mevalonate
and mimicked by geranylgeranyl transferase inhibitors
[40]. A recent study showed that pravastatin attenuates
ET1 constrictor response in small rat vessels through
enhanced NO release [41]. Therefore, statins may
contribute to the prevention of grafts’ spasm post
CABG.
Statin treatment could potentially affect platelet acti-
vation and thrombus formation, which is an important
mechanism for acute failure of SVGs. In a porcine model
of carotid injury, intravenous lovastatin acutely inhibited
platelet aggregation and thrombus formation [42]. Treat-
ment of hypercholesterolemic individuals with a statin
attenuated thromboxane-dependent platelet activation
[43] and modified platelet aggregation by ameliorating
their intracellular redox state [44]. In this way, statin
administration could provide SVGs with additional pro-
tection against acute thrombosis, independently of their
LDL-lowering effects.
Statins and intimal hyperplasia of SV grafts
Intimal hyperplasia is characterized by migration and
proliferation of VSMCs, accumulation of extracellular
matrix to the intima and finally plaque formation in the
SVGs [45]. Treatment of isolated human venous VSMCs
with a statin, attenuated the ability of VSMCs to pro-
liferate, through a mevalonate-reversible mechanism
[26], and suppressed the formation of vein graft intimal
hyperplasia by preventing Rho/ROCK activation specifi-
cally in endothelial cells [46]. In line to these findings, in
an ex vivo model of human vein VSMC cyclic stretch,
statins prevented proliferation by inhibiting the RhoA/
ROCK pathway [47]. In human venous VSMCs, the same
mechanism mediated the simvastatin-induced inhibition
of matrix metalloproteinase-9 secretion, an enzyme which
is implicated in intimal hyperplasia [48].f statins in endothelial cells. (b) The mevalonate pathway and effects of
aryl-coenzyme A; DAPP: dimethylallyl pyrophosphate; IPP: isopentenyl-5
GGPP: geranyl-geranyl pyrophosphate; GTP: guanosine-50-triphosphate;
terin; O2
: superoxide; eNOS: endothelial nitric oxide synthase; iNOS:
hosphoinositide 3-kinase; Akt: protein kinase B; GTPCH: GTP-
L: low density lipoprotein; oxLDL: oxidized LDL; ROS: reactive oxygen
se.
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It is well established that atherosclerosis is primarily an
inflammatory process involving migration of monocytes
from the circulation to the subendothelial space, due to
increased levels of proinflammatory cytokines and cell
adhesion molecules. LDL is oxidized to ox-LDL which is
up-taken by macrophages to form foam cells (Figure 1)
[19]. Incubation of human endothelial cells and mono-
cytes with simvastatin reduced chemokine receptor and
proinflammatory gene expression through inhibition of
protein geranylgeranylation [49]. HUVECs treated with
simvastatin displayed reduced TNFa-mediated mono-
cyte recruitment [50]. In addition, in a model of early
SVG arterialisation, simvastatin reduced the expression of
CD40 and its soluble ligand in a mevalonate-dependent
way [51]. In apolipoprotein E/LDL-receptor double
knockout mice, oral atorvastatin reduced circulating
levels of monocyte-chemoattractant protein 1 (MCP-1),
as well as vascular cell adhesion molecule-1 (VCAM-1)
and intercellular cell adhesion molecule-1 (ICAM-1) in
atherosclerotic lesions [52]. In normocholesterolemic
humans, treatment with simvastatin attenuated monocyte
recruitment through inhibition of CC chemokine recep-
tor 2 (CCR2) [53].
Statins and regulation of redox state in SV grafts
Increased vascular oxidative stress is a major determinant
of endothelial dysfunction and atherosclerosis, thus con-
stituting a promising therapeutic target [54]. A major
cellular enzymatic source of ROS in the vasculature is
NADPH-oxidase, which is an enzymatic complex catalys-
ing the formation of superoxide from molecular oxygen by
reducing NADPH (Figure 1). Different structural isoforms
of the enzyme exist, depending on the homologue of the
membrane-bound catalytic subunit gp91phox, now known
as Nox1, Nox2, 4 and 5 are abundant in endothelial cells,
whereas Nox1, 2 and 4 can be found in VSMCs [55]
(Figure 1). Nox1, 2 and 4 are activated after translocation
of the cytosolic subunits to the membrane through the
action of the small GTPase Rac. In animal models, ator-
vastatin treatment ameliorated vascular redox state [33]
and attenuated hypertension [56] by inhibiting the acti-
vation of Nox isoforms. We demonstrated that high dose
atorvastatin treatment pre-CABG, significantly reduced
total and NADPH-oxidase derived vascular superoxide
in human SVGs [25]. This was mediated by a mevalo-
nate-reversible reduction in Rac1 activation and its associ-
ated membrane translocation [25].
Mitochondria-derived ROS are increasingly recognized as
an important contributor to vascular oxidative stress, with
a significant role in atherosclerosis development [57];
statin treatment reduced mitochondrial superoxide
generation in SVGs from advanced CAD patients [22].
Statins improve vascular redox state not only through
reduction of LDL cholesterol and inhibition of pro-oxidantwww.sciencedirect.com
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endogenous antioxidant defences. In hypercholesterole-
mic rabbits, atorvastatin treatment increases erythrocyte
and liver glutathione (GSH) levels [58]. In both HUVECs
and streptozotocin-diabetic mice, statins upregulated cat-
alase expression [30]. Treatment of rat and human VSMCs
with simvastatin increased levels of heme-oxygenase 1
(HO-1), an important antioxidant enzyme that mediates
some of the anti-inflammatory effects of statins [59]. In a
randomized trial, simvastatin significantly increased extra-
cellular superoxide dismutase (SOD) activity compared to
ezetimibe [23]. Similarly, atorvastatin significantly
increased endothelial SOD activity in an observational
study of heart failure patients [60].
Through their effects on vascular redox state, statins also
affect redox-sensitive transcriptional pathways within the
vasculature, such as nuclear factor kappa-b (NF-kB) and
activator protein 1 (AP1) (Figure 1). These pathways
induce the expression of various proinflammatory, pro-
thrombotic and overall proatherogenic molecules in the
vascular wall, such as cytokines, chemokines, adhesion
molecules and others [55]. NF-kB is activated by oxi-
dative stress and pro-inflammatory stimuli in a GGPP/
FPP-dependent way [55]. Statins have been shown to
inhibit NF-kB activation, both in endothelial cells and
VSMCs, by modifying the intracellular redox state and
increasing the levels of NF-kB inhibitor IkB [61]. In this
way, statins could attenuate the atherosclerotic process in
SVGs by synergistically affecting both oxidative stress
and inflammation.
Therefore, statins exert multiple effects on redox state of
SVGs, by improving endogenous antioxidant defences
and suppressing the enzymatic sources responsible for
ROS generation in the vascular wall. Whether suppres-
sion of redox signalling in the wall of these grafts is related
with improved patency and better clinical outcome
remains to be documented.
Differential effects of lipophilic vs. hydrophilic
statins: the concept of ‘vascular’ statins
Uptake of statins from hepatocytes, which are the major
sites of LDL production, depends on both active transport
and passive diffusion [62]. However, this may not be true
for non-hepatic cells, where the choice of statin admini-
strated could significantly influence drug levels achieved
inside the cells [19]. More specifically, lipophilic statins
such as atorvastatin and simvastatin (also called ‘vascular
statins’ [63]) are more easily diffused across cellular mem-
branes than hydrophilic statins such as rosuvastatin, an
effect which could potentially explain some of the
observed effects of the aforementioned statins on the
vasculature. A comparative study involving ex vivo incu-
bation of primary human VSMCs with various statins found
a significant protective effect of lipophilic but not of
hydrophilic statins on cell migration and proliferationwww.sciencedirect.com [64]. A very recent review elegantly presents comparisons
between different statins on experimental models and
clinical studies [65]. These data suggest that care should
be taken not only in choosing the correct dosage but also
the correct type of statin, for optimal outcome on SVG
patency after a CABG.
Conclusions
Coronary bypass grafting is still considered to be a first
line option for the treatment of multi-vessel CAD, especi-
ally in patients with diabetes or impaired left ventricular
systolic function [15]. Although IMA is the ideal graft
routinely used for the revascularization of left anterior
descending coronary artery, the presence of multiple
stenoses requires the use of additional grafts. Currently,
SVGs are routinely used by most surgical teams, but their
short-term and long-term patency rates are much lower
than IMAs. It is therefore important to identify new
pharmaceutical strategies targeting SVGs’ biology that
would improve the patency of these grafts.
Statins undoubtedly improve clinical outcome in second-
ary prevention and especially in patients undergoing
coronary revascularization, either by PCI or CABG [7].
Since statins exert a number of pleiotropic effects on the
vascular wall, beyond lipid lowering, one could hypoth-
esize that statins may have a similar effect on SVGs as
well. Indeed, statins reduce vascular oxidative stress in
SVGs, improve NO bioavailability and reduce vascular
inflammation, all critical components of SVGs failure [19].
In addition, statins have systemic antithrombotic and
anti-inflammatory effects [49]; therefore, their adminis-
tration may prevent acute SVGs failure post CABG.
In conclusion, statins provide a particularly useful
pharmacological intervention in secondary prevention
and improve clinical outcome post-CABG. This is partly
due to their beneficial effect on SVGs biology, although
more studies are required to explore in detail the mol-
ecular mechanisms by which statins affect short-term and
long-term patency in human SVGs. This will identify
novel therapeutic targets in these grafts, and may lead to
the development of new pharmacological strategies tar-
geting SVG biology in the future.
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